© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.
Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.
ViiV applies for FDA approval of HIV drug fostemsavir
The attachment inhibitor performed well as an adjunct to an optimized antiretroviral regimen among those with multidrug-resistant HIV.
The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.